ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±Ò¶»Ûݼ¡¢¹Ø¼ÒÆæ¡¢ÌÆÑÞÀö£©ÈÕǰ£¬ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÔÚÖé½Ð³ÇÔºÇøÊµÑéÂ¥ÕÙ¿ªÃ½ÌåÐû²¼»á£¬½éÉÜÆä×îеÄÑо¿Ð§¹û¡ª¡ªngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÑʤ½ÌÊÚÍŶӺ͸´µ©´óѧÁ¥ÊôÑÛ¶ú±Çºí¿ÆÒ½ÔºÇ®½½ÌÊÚÍŶÓÔÚ¹ú¼Ê¶¥¼¶Ò½Ñ§ÆÚ¿¯ÃÀ¹úҽѧ»áÔÓÖ¾£¨JAMA£©½ÒÏþÔ´´ÁÙ´²Ñо¿ÂÛÎÄ£¬Ö¤ÊµÁË¡°3¸öÁƳ̵ÄCEV»¯ÁÆ·½°¸Óë¹Å°å6ÁƳ̷½°¸¹ØÓÚ¸ßΣÊÓÍøÄ¤Ä¸Ï¸°ûÁö¾ßÓÐÏàͬµÄÁÆÐ§¡±¡£¡£¡£Ðû²¼»áÓÉngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÖ÷ÈΡ¢Ò½ÔºÔº³¤¡¢ÑÛ²¡·ÀÖÎÌìÏÂÖØµãʵÑéÊÒÖ÷ÈÎÁÖºÆÌí½ÌÊÚÖ÷³Ö£¬ÏîÄ¿ÈÏÕæÈË¡¢ÂÛÎÄ×îºóͨѶ×÷ÕßÑʤ½ÌÊÚ½éÉܸÃÑо¿Ð§¹û¡£¡£¡£

Ñо¿ÍŶÓ
ÊÓÍøÄ¤Ä¸Ï¸°ûÁöÊǶùͯÑÛÄÚ×î³£¼ûµÄ¶ñÐÔÖ×Áö£¬È«ÌìÏÂÿÄêÔ¼ÓÐ8000ÀýÐÂÔö»¼¶ù¡£¡£¡£¾ßÓв¡Àí¸ßΣÒòËØµÄÍíÆÚÊÓÍøÄ¤Ä¸Ï¸°ûÁö»¼¶ùÓнϸߵÄÂÄÚÒÔ¼°Ô¶´¦×ªÒÆ·çÏÕ£¬ÕâÐ©×ªÒÆ³£µ¼Ö²¡ÇéѸËÙ¶ñ»¯£¬ÑÏÖØÍþв»¼¶ùÉúÃü¡£¡£¡£ÏÖÔÚ¹ØÓÚÕâÀ໼¶ùÖ÷ÒªµÄÖÎÁÆ·½°¸ÎªÊõºó¸¨Öú»¯ÁÆ¡£¡£¡£µ«ÓÉÓÚȱ·¦Õë¶Ô¾ßÓв¡Àí¸ßΣÒòËØµÄÍíÆÚÊÓÍøÄ¤Ä¸Ï¸°ûÁö»¼¶ùµÄÁÙ´²Ëæ»úÊÔÑéÊý¾Ý£¬ÏÖÔÚÉÐÎÞ·¨È·¶¨×î¼ÑµÄ»¯ÁÆÁƳ̡£¡£¡£
¹Å°åµÄ6¸öÁƳÌCEV£¨¿¨²¬¡¢ÒÀÍв´Üպͳ¤´ºÐ¼·½°¸ËäÈ»ÓÐÓ㬵«ÁƳ̹ý³¤¡¢²»Á¼·´Ó³¼°²¢·¢Ö¢½Ï¶à£¬¸ø»¼¶ùºÍÆä¼ÒÍ¥´øÀ´¼«Öصļ縺¡£¡£¡£ÎªÁËËõ¶ÌÁƳ̣¬ïÔÌ»¯ÁƸ±×÷Ó㬼õÇỼ¶ùºÍ¼ÒÍ¥µÄ¼ç¸º£¬Ñʤ½ÌÊÚÍŶӿª´´ÐÔµØÌá³öÁË3¸öÁƳÌCEV»¯ÁÆ·½°¸£¬²¢Ì½Ë÷Á˱¾·½°¸Óë¹Å°å·½°¸ÊÇ·ñ¾ßÓÐÏàͬµÄÓÐÓÃÐÔ¡£¡£¡£
¿ËÈÕ£¬ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÑʤ½ÌÊÚÍŶÓÁªºÏ¸´µ©´óѧÁ¥ÊôÑÛ¶ú±Çºí¿ÆÒ½ÔºÇ®½½ÌÊÚÍŶÓÔÚ¹ú¼Ê¶¥¼âҽѧÆÚ¿¯JAMA½ÒÏþÁËÌâΪ¡°Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma £º£º£ºA Randomized Clinical Trial¡±µÄÑо¿ÂÛÎÄ¡£¡£¡£ÕâÏîÑо¿ÊÇngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÔÚJAMAÉϵĵڶþƪԴ´ÁÙ´²Ñо¿ÂÛÎÄ£¬Ò²ÊÇÎÒ¹úÑÛ¿ÆÁìÓòÔÚ¸ÃÆÚ¿¯½ÒÏþµÄµÚ¶þƪÁÙ´²Ñо¿ÂÛÖø¡£¡£¡£
±¾Ñо¿»Ø¸²Á˸ßΣÊÓÍøÄ¤Ä¸Ï¸°ûÁö»¼¶ùÊõºó¸¨Öú»¯ÁƵÄ×î¼ÑÁƳÌÎÊÌ⣬Ñо¿Ð§¹ûÅú×¢£¬3¸öÁƳ̵ÄCEV»¯ÁÆ·½°¸Óë¹Å°å·½°¸¾ßÓÐÏàͬµÄÁÆÐ§£¬ÕâÓÐÍûʹ¸ü¶à¸ßΣÊÓÍøÄ¤Ä¸Ï¸°ûÁö»¼¶ùÊÜÒæ²¢Ð´ÈëÖ¸ÄÏ¡£¡£¡£
ÕâÏîǰհÐÔ¡¢·ÇÁÓÐ§Ëæ»ú±ÈÕÕÁÙ´²Ñо¿ÄÉÈëÁË187Àý½ÓÊÜÑÛÇòÕª³ýÊõÇÒ¾ßÓв¡Àí¸ßΣÒòËØµÄµ¥ÑÛÊÓÍøÄ¤Ä¸Ï¸°ûÁö»¼¶ù¡£¡£¡£»£»£»¼¶ùËæ»ú·ÖΪÁ½×飬»®·Ö½ÓÊÜ3¸öÁƳ̻ò6¸öÁƳ̵ÄCEV»¯ÁÆ¡£¡£¡£Ñо¿µÄÖ÷Ҫϳ¡Ö¸±êΪÎÞ²¡ÉúÑÄÂÊ£¨DFS£©£¬´ÎҪϳ¡Ö¸±êΪ×ÜÉúÑÄÂÊ¡¢Çå¾²ÐÔ¡¢¾¼Ã¼ç¸º¡£¡¢»¼¶ùÉúÑÄÖÊÁ¿µÈ¡£¡£¡£
Ñо¿Ð§¹ûÏÔʾ£¬ÔÚÖ÷Ҫϳ¡Ö¸±ê£¨5ÄêÎÞ²¡ÉúÑÄÂÊ£©·½Ã棬3ÁƳÌ×éºÍ6ÁƳÌ×é»®·ÖΪ90.4%ºÍ89.2%£¬ÎÞÏÔÖø²î±ð¡£¡£¡£±ðµÄ£¬ÔÚ5Äê×ÜÉúÑÄÂÊ·½Ã棬Á½×éÒ²ÎÞͳ¼ÆÑ§²î±ð£¨91.5% VS 89.3%£©¡£¡£¡£


3ÁƳÌ×é±ÈÕչŰå6ÁƳÌ×飬ÎÞ²¡ÉúÑÄÂÊÎÞÏÔÖø²î±ð
ÔÚÖÎÁÆÇå¾²ÐÔ·½Ã棬3ÁƳÌ×éÓÐ79Ãû£¨80.6%£©»¼¶ùÂÄÀúÁ˹²282´Î²»Á¼ÊÂÎñ¡£¡£¡£¶øÔÚ6ÁƳÌ×éÖУ¬89Ãû»¼¶ù£¨95.7%£©ÂÄÀúÁË×ܼÆ681´Î²»Á¼ÊÂÎñ¡£¡£¡£±ðµÄ£¬ÔÚ¾¼Ã¼ç¸º·½Ã棬3ÁƳÌ×é±È6ÁƳÌ×éÖ±½Ó±¾Ç®ºÍ¼ä½Ó±¾Ç®¸üµÍ¡£¡£¡£
±¾Ñо¿Ö¤Êµ£¬3¸öÁƳÌCEV»¯ÁÆÔÚÔ¤·À×ªÒÆºÍ½µµÍéæÃüÂÊ·½ÃæÓë6¸öÁƳÌͬÑùÓÐÓã¬ÇÒ¸±×÷ÓøüÉÙ£¬±¾Ç®¸üµÍ¡£¡£¡£
Õâ¿ÉÄܳÉΪ¡°¾ßÓиßΣ²¡ÀíÌØÕ÷µÄÊÓÍøÄ¤Ä¸Ï¸°ûÁö¡±µÄÖÎÁÆÐ±ê×¼£¬ÓÐÍûʹ¸ü¶à»¼¶ùÊÜÒæ£¬²¢¿ÉÄܱ»Ð´Èë¹ú¼ÊÖ¸ÄÏ¡£¡£¡£
JAMAÆÚ¿¯¶Ô±¾Ñо¿¸øÓèÁË¸ß¶ÈÆÀ¼Û£¬ÒÔΪÕâÏîÑо¿¶ÔÓÐÊýÖ×ÁöÖÎÁƾßÓÐÖØ´óÒâÒå¡£¡£¡£¹ú¼Ê¶¥¼¶ÑÛÖ×Áöר¼ÒCarol Lally Shields½ÌÊÚ̸Â۳ƣ¬¸ÃÑо¿µÄ3¸öÁƳÌCEV»¯ÁÆ·½°¸ÊÇÀï³Ì±®Ê½µÄ£¬ÓÉÓÚËü¼ÈÕü¾ÈÁËÉúÃü£¬ÓÖ¼õÇáÁË»¼Õߵľ¼ÃѹÁ¦£¬Ìá¸ßÁËÖÎÁÆÍê³ÉÂÊ¡£¡£¡£
ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄ¡¢ÑÛ²¡·ÀÖÎÌìÏÂÖØµãʵÑéÊÒΪ±¾Ñо¿µÚÒ»×÷Õßµ¥Î»ºÍ×îºóͨѶ×÷Õßµ¥Î»¡£¡£¡£ÖÐɽÑÛ¿ÆÖÐÐÄÑʤ½ÌÊں͸´µ©´óѧÁ¥ÊôÑÛ¶ú±Çºí¿ÆÒ½ÔºÇ®½½ÌÊÚΪÅäºÏͨѶ×÷Õߣ¬ÖÐɽÑÛ¿ÆÖÐÐĸ±Ö÷ÈÎҽʦҶ»Ûݼ¡¢¸´µ©´óѧÁ¥ÊôÑÛ¶ú±Çºí¿ÆÒ½Ôº¸±Ö÷ÈÎҽʦѦ¿µÎªÅäºÏµÚÒ»×÷Õß¡£¡£¡£
ÂÛÎÄÁ´½Ó£º£º£º
https://jamanetwork.com/journals/jama/article-abstract/2825162